Definitive Healthcare Corp. filings document the regulatory disclosures of a public healthcare data and analytics software company. Recent Form 8-K reports furnish quarterly and annual financial-result releases covering revenue, net loss, adjusted profitability measures, cash flow, guidance, and impairment-related disclosures tied to the company’s subscription-based commercial intelligence platform.
The filing record also includes definitive proxy materials for annual stockholder matters, board elections, executive compensation, equity awards, and governance practices. Other material-event filings document board and committee composition changes, executive-role and compensation arrangements, and the termination of a nominating agreement affecting director-designation rights.
Definitive Healthcare Corp. is asking stockholders to vote at its June 4, 2026 annual meeting on four key items. Stockholders will elect three Class II directors, ratify Deloitte & Touche LLP as independent auditor for 2026, and cast an advisory vote on executive pay.
The company also seeks approval to amend its 2021 Equity Incentive Plan to increase the share reserve by 15,000,000 shares of Class A common stock, from 30,972,789 to 45,972,789, supporting future equity grants to employees, directors, and consultants.
Definitive Healthcare Corp. reported that it has ended a prior governance arrangement with an affiliate of Spectrum. The company and SE VII DHC AIV, L.P. entered into a termination agreement on April 3, 2026 that permanently and irrevocably ended their 2021 Nominating Agreement.
That Nominating Agreement had allowed Spectrum, while it beneficially owned at least 5% of the company’s outstanding common stock, to designate one person for inclusion in the board slate (the “Spectrum Designee”). Jeff Haywood, the Spectrum Designee, resigned from the board on March 30, 2026, and the nominating rights have now been fully terminated.
Definitive Healthcare Corp. CEO Kevin Coop had 37,593 shares of Class A Common Stock withheld on April 1 to cover tax obligations tied to vesting RSUs. This was a tax-withholding disposition, not an open-market sale. After this event, he directly holds 5,078,872 shares.
Definitive Healthcare Corp. director and executive chairman Jason Ronald Krantz had 45,154 shares of Class A Common Stock withheld on April 1, 2026 at $1.09 per share to cover tax obligations tied to the vesting of previously reported RSUs. This was a tax-withholding disposition, not an open-market sale, and was satisfied by the issuer delivering shares for the liability.
After this event, Krantz directly held 1,213,604 shares of Class A Common Stock. He also beneficially owned an additional 450,000 shares held in trust by DH Holdings (f/k/a Jason R. Krantz 2009 Trust), of which he is the beneficiary.
Definitive Healthcare Corp. reported that on March 30, 2026, director Jeff Haywood resigned from its Board of Directors and from the Board’s Human Capital Management and Compensation Committee, effective immediately. The company stated that his resignation was not due to any disagreement regarding its operations, policies, or practices.
Following his departure, the Board size was reduced from nine members to eight members, and the Compensation Committee was reduced from three members to two members, reflecting his departure rather than adding a replacement director at this time.
Definitive Healthcare Corp. reported that Chief Executive Officer Kevin Coop had 175,524 shares of Class A common stock withheld by the company at $1.28 per share. These shares were retained by the issuer to cover Coop's tax withholding obligations tied to the vesting and settlement of previously reported restricted stock units, rather than being sold in an open-market transaction. After this tax-withholding disposition, Coop directly holds 5,116,465 shares of Definitive Healthcare common stock.
Graboske Benjamin reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that EVP and Chief Data Officer Benjamin Graboske received a grant of 631,068 restricted stock units (RSUs) of Class A Common Stock. The award was recorded at a price of $0.00 per share, reflecting stock-based compensation rather than a cash purchase.
Each RSU represents a contingent right to receive one share of Class A Common Stock. According to the disclosure, 25% of these RSUs are scheduled to vest on March 1, 2027, with additional vesting at a rate of 6.25% thereafter. Following this grant, Graboske’s directly owned Class A Common Stock, including RSUs, totaled 1,312,026.654 shares.
Paris Jonathan reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that Chief Legal Officer Jonathan Paris received a grant of 481,505 restricted stock units, each representing one share of Class A common stock. According to the award terms, 25% of these RSUs vest on March 1, 2027, with 6.25% vesting every three months over the following three years, contingent on his continued service.
Heller Casey reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp.’s Chief Financial Officer, Casey Heller, reported an equity award of 733,301 restricted stock units (RSUs) tied to the company’s Class A common stock at a stated price of $0.00 per share. Each RSU represents a contingent right to receive one share.
According to the filing, 25% of these RSUs will vest on March 1, 2027, with an additional 6.25% vesting every three months over the following three years, as long as Heller remains in service. After this grant, Heller directly holds 2,007,322 shares or RSUs linked to Class A common stock.